Liquid biopsy, big data and artificial intelligence as a new global clinical trial model in targeted therapy

To this day, the phase III trial continues to be, as it was more than 60 years ago, the standard for the incorporation of new treatments in oncology. We currently have new tools such as NGS, Liquid Biopsy (LB), Big Data (BD) and Artificial Intelligence (AI) that will allow us to move towards faster...

Full description

Saved in:
Bibliographic Details
Main Authors: Albert Abad, Joana Vidal, Laura Layos, Cesar Morcillo, Izar Achaerandio, Santiago Viteri
Format: Article
Language:English
Published: Elsevier 2023-09-01
Series:The Journal of Liquid Biopsy
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2950195423000085
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846160170200072192
author Albert Abad
Joana Vidal
Laura Layos
Cesar Morcillo
Izar Achaerandio
Santiago Viteri
author_facet Albert Abad
Joana Vidal
Laura Layos
Cesar Morcillo
Izar Achaerandio
Santiago Viteri
author_sort Albert Abad
collection DOAJ
description To this day, the phase III trial continues to be, as it was more than 60 years ago, the standard for the incorporation of new treatments in oncology. We currently have new tools such as NGS, Liquid Biopsy (LB), Big Data (BD) and Artificial Intelligence (AI) that will allow us to move towards faster and more universal research. This article analyzes the important weaknesses of phase III trials, the importance and current status of targeted therapy, and the contributions to LB decision-making and the knowledge of what happens in real life (RWD) that we facilitates BD and AI. Finally, what could be a clinical trial model that would take advantage of all these tools is proposed.
format Article
id doaj-art-0eca988e0e7d433fb838abaf6ffc7f3f
institution Kabale University
issn 2950-1954
language English
publishDate 2023-09-01
publisher Elsevier
record_format Article
series The Journal of Liquid Biopsy
spelling doaj-art-0eca988e0e7d433fb838abaf6ffc7f3f2024-11-22T07:40:58ZengElsevierThe Journal of Liquid Biopsy2950-19542023-09-011100008Liquid biopsy, big data and artificial intelligence as a new global clinical trial model in targeted therapyAlbert Abad0Joana Vidal1Laura Layos2Cesar Morcillo3Izar Achaerandio4Santiago Viteri5UOMI Cancer Center, MiTres Torres, Barcelona, Spain; Corresponding author. UOMI Cancer Center, MiTres Torres, C/ Doctor Roux 76, 08017 Barcelona. Spain.Medical Oncology Department, Hospital del Mar Research Institute, CIBERONC, Barcelona, SpainMedical Oncology Department, Catalan Institute of Oncology (ICO) Applied Research Group in Oncology (B-ARGO), Germans Trias i Pujol University Hospital, Badalona, Barcelona, SpainHospital Digital, Hospital Sanitas CIMA, Barcelona, SpainInstitut Clinic de Malalties Hemato-Oncologiques, Hospital Clinic, Barcelona, SpainUOMI Cancer Center, MiTres Torres, Barcelona, SpainTo this day, the phase III trial continues to be, as it was more than 60 years ago, the standard for the incorporation of new treatments in oncology. We currently have new tools such as NGS, Liquid Biopsy (LB), Big Data (BD) and Artificial Intelligence (AI) that will allow us to move towards faster and more universal research. This article analyzes the important weaknesses of phase III trials, the importance and current status of targeted therapy, and the contributions to LB decision-making and the knowledge of what happens in real life (RWD) that we facilitates BD and AI. Finally, what could be a clinical trial model that would take advantage of all these tools is proposed.http://www.sciencedirect.com/science/article/pii/S2950195423000085Liquid biopsyFase IIITargeted therapyBig dataArtificial intelligence
spellingShingle Albert Abad
Joana Vidal
Laura Layos
Cesar Morcillo
Izar Achaerandio
Santiago Viteri
Liquid biopsy, big data and artificial intelligence as a new global clinical trial model in targeted therapy
The Journal of Liquid Biopsy
Liquid biopsy
Fase III
Targeted therapy
Big data
Artificial intelligence
title Liquid biopsy, big data and artificial intelligence as a new global clinical trial model in targeted therapy
title_full Liquid biopsy, big data and artificial intelligence as a new global clinical trial model in targeted therapy
title_fullStr Liquid biopsy, big data and artificial intelligence as a new global clinical trial model in targeted therapy
title_full_unstemmed Liquid biopsy, big data and artificial intelligence as a new global clinical trial model in targeted therapy
title_short Liquid biopsy, big data and artificial intelligence as a new global clinical trial model in targeted therapy
title_sort liquid biopsy big data and artificial intelligence as a new global clinical trial model in targeted therapy
topic Liquid biopsy
Fase III
Targeted therapy
Big data
Artificial intelligence
url http://www.sciencedirect.com/science/article/pii/S2950195423000085
work_keys_str_mv AT albertabad liquidbiopsybigdataandartificialintelligenceasanewglobalclinicaltrialmodelintargetedtherapy
AT joanavidal liquidbiopsybigdataandartificialintelligenceasanewglobalclinicaltrialmodelintargetedtherapy
AT lauralayos liquidbiopsybigdataandartificialintelligenceasanewglobalclinicaltrialmodelintargetedtherapy
AT cesarmorcillo liquidbiopsybigdataandartificialintelligenceasanewglobalclinicaltrialmodelintargetedtherapy
AT izarachaerandio liquidbiopsybigdataandartificialintelligenceasanewglobalclinicaltrialmodelintargetedtherapy
AT santiagoviteri liquidbiopsybigdataandartificialintelligenceasanewglobalclinicaltrialmodelintargetedtherapy